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Cot, initially identified as an oncogene in a truncated form, is a mitogen-activated protein kinase kinase
kinase implicated in cellular activation and proliferation. Here, we show that this truncation of Cot results in
a 10-fold increase in its overall kinase activity through two different mechanisms. Truncated Cot protein
exhibits a lower turnover rate (half-life, 95 min) than wild-type Cot (half-life, 35 min). The degradation of
wild-type and truncated Cot can be specifically inhibited by proteasome inhibitors in situ. The 20S proteasome
also degrades wild-type Cot more efficiently than the truncated protein. Furthermore, the amino acid 435 to 457
region within the wild-type Cot COOH-terminal domain confers instability when transferred to the yellow
fluorescent protein and targets this fusion protein to degradation via the proteasome. On the other hand, the
kinase specific activity of wild-type Cot is 3.8-fold lower than that of truncated Cot, and it appears that the last
43 amino acids of the wild-type Cot COOH-terminal domain are those responsible for this inhibition of kinase
activity. In conclusion, these data demonstrate that the oncogenic activity of truncated Cot is the result of its
prolonged half-life and its higher kinase specific activity with respect to wild-type Cot.
The Cot/tpl-2 gene encodes a mitogen-activated protein
(MAP) kinase kinase kinase that is potentially capable of
switching on several MAP kinase cascades, namely those lead-
ing to the activation of the MAP kinases ERK1/ERK2, JNK,
p38, and ERK5 (13, 20, 25, 38, 47, 53). These signal trans-
duction pathways link Cot activity with the up-regulation of
several transcription factors, such as AP-1 (7, 13, 25), NFAT
(7, 17, 62), NF-B (8, 31, 38, 63), CREB (22), or E2F (65). As
a result, Cot activity has been implicated in cellular activation
as well as cell proliferation through the regulation of the cell
cycle transitions G0/G1 and G1/S (6, 7, 20, 46, 54, 63, 65).
Cot has also been implicated in cellular transformation, as
the genomic locus of the Cot gene is amplified in some human
breast cancers (58) and malignant human Hodgkin/Reed-
Sternberg cells exhibit abnormally high expression levels of Cot
protein (21). The human Cot gene was originally identified in
its truncated form, which is present in transformed SHOK cell
foci obtained by the transfection of the genomic DNA from a
human thyroid carcinoma cell line (42). This truncation un-
masks the transforming capacity of this proto-oncogene, a
property of the truncated Cot protein (trunc-Cot) in which the
last 69 amino acids of the wild-type (wt) COOH-terminal (C-
terminal) domain are replaced by an unrelated 18-amino-acid
sequence (42). Nevertheless, it has since been shown that over-
expression of the proto-oncogenic form is also capable of con-
ferring a transformed phenotype to established cell lines (12,
13).
The rat homologue of the human Cot gene is the tpl-2 gene.
Disruption of the last coding exon of tpl-2, due to the insertion
of the Moloney leukemia provirus (MLV), leads to the expres-
sion of a truncated protein where the final 44 amino acids of
the C-terminal domain of the normal cellular protein are re-
placed by a 10-amino-acid fragment of unrelated sequence.
The truncation of the tpl-2 gene by the MLV insertion also
unmasks its oncogenic potential (11, 40, 46). The C-terminal
domains of both wt Cot and tpl-2 are almost identical. The only
difference between the last 77 C-terminal amino acids of the
human wt Cot and tpl-2 are the two conservative substitutions
M437 for V and K439 for R. However, there is no similarity in
the amino acids inserted in either trunc-Cot or trunc-tpl-2.
Similarly, integration of the mouse mammary tumor provirus
(MMTV) in the last intron of the mouse tpl-2 gene has also
been implicated in epithelial cell transformation (23).
The tightly regulated expression of short-lived proteins im-
plicated in specific signal transduction pathways is essential for
the correct control of proliferation. Moreover, a deregulation
of the turnover of these proteins can trigger transformation
(34). Many such proteins are degraded by the proteasome (14,
27, 32, 34, 67), and an important aspect of their degradation is
the identification of signals responsible for their efficient tar-
geting to the proteasome machinery (68). Indeed, this kind of
highly regulated degradation of specific proteins is often me-
diated by discrete regions of their primary sequences known as
degrons (64). In most instances, a degron can function auton-
omously when inserted within the sequence of a heterologous
protein, triggering to degradation the fusion protein by the
same mechanisms that operate in the original substrate (24, 29,
33). The vast majority of proteins degraded by the proteasome
are first modified by a set of enzymes that attach multiple
copies of ubiquitin (for a review, see references 28 and 59).
However, there are proteins, such as p21waf1 (60), ornithine
decarboxylase (15, 66), casein (50), myelin basic protein (3,
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39), and IB (36), that can be degraded via the proteasome
without prior ubiquitylation.
In this paper, we demonstrate that the C-terminal domain of
wt Cot regulates its kinase activity by two different mecha-
nisms. The amino acids 435 to 457 within the C-terminal do-
main of wt Cot contain a signal that targets this protein to
proteasome degradation. Thus, wt Cot is expressed at steady-
state levels that are 2.6-fold lower than those of trunc-Cot. On
the other hand, wt Cot exhibits 3.8-fold lower specific kinase
activity than trunc-Cot, indicating that the region encompassed
by the amino acid 425 to 467 region within the C-terminal do-
main exercises an inhibitory control on its kinase activity. Con-
sequently, transfected trunc-Cot cells exhibit a 10-fold-higher
Cot activity per mg of total protein and a greater capacity to
produce cell transformation than wt Cot transfected cells.
These results provide an explanation of the molecular basis for
the enhanced transformation capability of the trunc-Cot protein.
MATERIALS AND METHODS
Plasmids. pcINEO HA-wt Cot (1 to 467), pcINEO HA-trunc-Cot, pcINEO
HA plasmids (65), pEF-BOS wt Cot, pEF-BOS trunc-Cot (6, 7), and 73
pcol-Luc (7) have all been described previously. The GST-Cot390-467 construct
containing the C-terminal domain of wt Cot fused to the C terminus of gluta-
thione S-transferase (GST) was constructed by subcloning a PCR fragment of wt
Cot into the pGEX4T3-GST plasmid (Amersham-Pharmacia-Biotech). The se-
quences of the primers used were as follows: F, 5-GGCCCTGAAttCGCCC
AGAG (where the lowercase letters indicate the mismatches to generate the
EcoRI site for cloning); and R, 5-CAAGACGACGcAgcTGGTTGTCCCCG
(where the lowercase letters indicate the mismatches to generate the SalI site for
cloning). The EcoRI- and SalI-digested PCR product was also inserted into the
pEYFP-C1 plasmid (Clontech) to obtain EYFP-Cot390-467, in which the C ter-
minal (390 to 467) of wt Cot is fused to the C terminus of EYFP. The different
HA-Cot and EYFP-Cot constructs, with different stop codons (namely HA-
Cot457 or EYFP-Cot390-457, HA-Cot446 or EYFP-Cot390-446, HA-Cot435 or
EYFP-Cot390-435, and HA-Cot424 or EYFP-Cot390-424) were generated by in
vitro-directed mutagenesis using the QuikChange directed mutagenesis kit and
the following primers, respectively: forward (F) 5-GGCTACTTCAATCTTtga
CGGGGACCACCAACGCTT-3 and reverse (R) 5-AAGCGTTGGTGGTCC
CCGtcaAAAGATTGAAGTAGCC-3; F 5-CGCTCTCTC TACATCtAaCTC
GGCGCTCTGGCTGGCTAC-3 and R 5-GTAGCCAGCCAGAGCGCCGA
GtTaGATGTAGAGAGAGCG-3; F 5-GGAAGCACCGAGGAATCTtAGA
TGCTCAAGAGGCAA-3 and R 5-TTGCCTCTTGATCATCTaAGATTCCT
CGGTGCTTCC-3; and F 5-GAGAACATTGCTtAaTCTTCGTGCACAGGA
AGCACCG-3 and R 5-CGGTGCTTCCTGTGCACGAAGAtTaAGCAATG
TTCTC-3 (where the lowercase letters indicate the mismatches to generate the
stop codon). EYFP-Cot445-457 was constructed by subcloning into the pEYFP-C1
plasmid the 5-phosphorylated oligonucleotides F (5gatcATCGACCTCGGCG
CTCTGGCTGGCTACTTCAATCTTTAG, where the lowercase letters indicate
the sequence for ligation to the BglII site) and R (5tcgaCTAAAGATTGAAG
TAGCCAGCCAGAGCGCCGAGGTCGATA, where the lowercase letters in-
dicate the sequence for ligation to the SalI site), which contain the nucleotides
corresponding to amino acids 445 to 457 of wt Cot. To obtain the three different
constructs EYFP-Cot414-457, EYFP-Cot426-457, and EYFP-Cot435-457, the HA-
Cot457 construct was used as a template to generate mutants with a BglII site in
the nucleotides corresponding to amino acids 413, 425, and 434. The different
mutants were obtained by in vitro mutagenesis using the following primers: to
generate the 413 BglII site, primers F (5AAGAGGCTGCTGAGTAGatctGA
GCTGGAACTTCCT) and R (5 AGGAAGTTCCAGctcaGATCTACTCAGC
AGCCTCTT); to generate the 425 BglII site, primers F (5CTTCCTGAGAAC
ATTGCTagaTCTTCGTGCACAGGAAGC) and R (5GCTTCCTGTGCACG
AAGAtctAGCAATGTTCTCAGGAA); and to generate the BglII site at amino
acid 434, primers F (5 ACAGGAAGCACCGAGagATCTGAGATG CTCAA
GAGG) and R (5CCTCTTGAGCATCTCAGAtcTCTCGGTGCTTCCTGT)
(where the lowercase letters indicate the mismatches to generate the BglII sites).
These three different HA-Cot457 constructs with a new BglII site in the nucleo-
tide corresponding to amino acid 413, 425, or 434 were subjected to digestion
with BglII and SalI, and the three cDNA fragments were inserted in the
pEYFP-C1 polylinker plasmid previously digested with BglII and SalI. All the
constructs were verified by automatic DNA sequencing. The pCMV-His-ubiq-
uitin construct was a generous gift of Dirk Bohmann and has been described
previously (61). HA-PKB-DD and PKB-CaaX were generous gifts from
Balduino Burgering (19). The 73 pcol-Luc plasmid has been described previ-
ously (reference 7 and references therein).
Cell transfection, labeling, and immunoprecipitation. HEK293 cells (Ameri-
can Type Culture Collection) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum at 37°C in a
humidified atmosphere of 10% CO2–90% air. The cells were grown in 100-mm
dishes and were transfected at 50% confluency. The transfection assays, unless
otherwise indicated, were performed with 10 g of DNA per 100-mm dish using
the DEAE-dextran–chloroquine method. Inhibition of proteases was achieved by
incubating the cells, 14.5 h after transfection, with different protease inhibitors
for 7.5 h. The final concentrations of the protease inhibitors were as follows: 20
M E64 (Boehringer Mannheim), 1 mM pefabloc AEBSF (Boehringer Mann-
heim), 20 M phosporamidon (Calbiochem), 10 M Z-AAF-CMK (Biomol), 20
M MG132 or 10 M lactacystin (Calbiochem), and 20 M LLMet (Sigma-
Aldrich). The phosphatidylinositol 3-kinase (PI3K) inhibitor LY 294002 (50 M;
Calbiochem) was added to the cells 2 h after transfection, and 8 h before lysis the
cell medium was changed and a mixture containing 50 M LY 294002, 100 g of
cycloheximide/ml with or without 10 M lactacystin was added to the cells. For
metabolic labeling, cells were cultured in methionine-, cysteine-, and glutamine-
free DMEM for 20 min and then exposed to a 20-min pulse with 250 Ci of
[35S]methionine and [35S]cysteine labeling mixture (Amersham-Pharmacia-Bio-
tech)/ml. Subsequently, the cells were cultured in DMEM supplemented with
10% fetal bovine serum, 0.8 mM methionine, and 0.3 mM cysteine for the chase
periods indicated in the figures. The proteasome inhibitors MG132 (20 M) or
lactacystin (10 M) were added 2 h before the pulse and maintained during the
chase periods as described previously (35). The radiolabeled cells were then
washed twice with 10 ml of ice-cold phosphate-buffered saline (PBS) and lysed in
200 l of ice-cold lysis buffer (50 mM HEPES [pH 7.4], 10% glycerol, 150 mM
NaCl, 1% NP-40, 50 mM -glycerophosphate, 1 mM sodium orthovanadate, 3
nM okadaic acid, 10 g of pepstatin A/l, 0.2 mM phenylmethylsulfonyl fluoride
[PMSF] plus 1 Complete mini inhibitors tablet [Roche]/10 ml). The cell lysates
were centrifuged at 24,100  g for 10 min at 4°C, and the supernatants, contain-
ing the same amount of protein (400 to 900 g), were subjected to immunopre-
cipitation with the antihemagglutinin (anti-HA) antibody covalently bound to
protein A-agarose for 2 h at 4°C. The protein A-agarose was then washed once
with ice-cold HNTG buffer (20 mM HEPES [pH 7.5], 10% glycerol [vol/vol],
0.1% Triton X-100) plus 200 mM NaCl and twice with the HNTG buffer plus 150
mM NaCl. The immunoprecipitated proteins were denatured with sodium do-
decyl sulfate (SDS) loading buffer and separated by SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) on a 10% gel. After drying the gel, the radiola-
beled proteins were visualized and quantified with an Instant Imager (Perkin-
Elmer). To determine the amounts of immunoprecipitated proteins, immuno-
blotting was performed with anti-Cot antibodies using 50 g of the distinct initial
supernatants and the first supernatant after removal of the immunoprecipitated
Cot, as described below. About 90% of the trunc-Cot and wt Cot was immuno-
precipitated under the conditions described above.
Western blotting. The transfected cells contained in one 100-mm dish were
washed with ice-cold PBS and divided into two halves. One half of the cells was
lysed in 200 l of ice-cold lysis buffer and centrifuged at 24,100  g for 10 min
at 4°C. A total of 35 g of protein from the supernatants of these cells was
resolved by SDS–10% PAGE (soluble proteins). The pellets from the above
extraction were directly solubilized in SDS loading buffer, and the volume cor-
responding to the same amount of soluble protein was also loaded onto an
SDS–10% PAGE (insoluble proteins). The other half of the cells was directly
resuspended in SDS loading buffer, and the volume corresponding to the same
amount of soluble proteins was also subjected to electrophoresis in SDS–10%
PAGE gels (total proteins). The separated proteins were transferred to polyvi-
nylidene difluoride (PVDF) membranes and probed with polyclonal anti-Cot (6),
monoclonal anti-Cot (Calbiochem), or monoclonal anti-	
 (Babco) antibodies.
As a control of protein loading in the SDS-PAGE gels, the PVDF membranes
were also probed with a polyclonal anti-protein disulfide isomerase (PDI) anti-
serum as described previously (44). Antibodies against ubiquitin were purchased
from Dako, and those against enhanced yellow fluorescent protein (EYFP) were
from Clontech. Western blotting for phospho-Erk (P-Erk) and total Erk-2 was
performed with specific anti-P-Erk (Santa Cruz) and anti-Erk-2 (Zymed) anti-
body, respectively. The anti-GST antibody was purchased from Sigma. The blots
were developed using chemiluminiscence (ECL; Amersham-Pharmacia-Bio-
tech), and the signals were quantified by optical densitometry using NIH Image
1.6 unless otherwise indicated.












RT-PCR. Total RNA was isolated from cells transfected with pcINEO HA-wt
Cot HA-trunc-Cot and pcINEO HA (20 h after transfection) with TRIzol
(Gibco-BRL) according to the manufacturers’ instructions. Two micrograms of
total RNA was subjected to reverse transcription-PCR (RT-PCR) analysis as
described previously (65), using -actin primers as internal control.
AP-1-driven transcription assay. Different concentrations of pEF-BOS wt
Cot, pEF-BOS trunc-Cot (0.01, 0.03, 0.1, or 0.3 g), normalized for the amount
of DNA with empty pEF-BOS, or 0.15 g of the different pcINEO Cot constructs
were cotransfected together with 0.15 g of 73 pcol-Luc into HEK293 cells.
Twenty hours after transfection Luc activity was measured as described previ-
ously (7).
Cot kinase assay. Cot kinase assays were performed as described previously (1,
53), but with some minor modifications. Cells transfected with pcINEO HA-Cot
constructs and pcINEO HA for 20 h were lysed in 500 l of ice-cold lysis buffer
(50 mM Tris-HCl [pH 7.5], 1 mM EDTA, 1 mM EGTA, 1% [vol/vol] Triton
X-100, 1 mM sodium orthovanadate [pH 10], 10 mM sodium glycerophosphate
[pH 7.4], 5 mM sodium pyrophosphate, 0.27 mM sucrose, 0.1% [vol/vol] -glyc-
erophosphate, 0.1% -mercaptoethanol, 1 mM microcystin-LR, 1 mM benzami-
dine, plus 1 Complete mini inhibitors tablet/10 ml [Roche]) and centrifuged at
24,100  g for 10 min at 4°C. Ten micrograms of the different supernatants was
incubated for 2 h with the anti-HA antibody covalently bound to protein A-aga-
rose. The proteins immunoprecipitated were washed twice with ice-cold lysis
buffer plus 0.5 M of NaCl, once with ice-cold lysis buffer, and finally with ice-cold
50 mM Tris HCl (pH 7.5), 0.1 mM EGTA, 0.03% Brij, 0.1% (vol/vol) -mer-
captoethanol. The agarose beads were then incubated in a final volume of 20 l
containing 12.5 mM Tris (pH 7.5), 0.0075% Brij, 0.025 mM EGTA, 0.0158 g of
MKK1/l, 0.033 g of MAPK/l, 0.0025 mM microcystin-LR, 0.067 mM sodium
orthovanadate, 0.025% (vol/vol) -mercaptoethanol. The kinase reaction was
then started by adding a mixture of ATP and MgCl2 to final concentrations of
330 M and 6.5 mM, respectively, and was left to continue for 15 min at 30°C
with agitation. During this period of time the kinase reaction was linear. Two
microliters of this kinase reaction was then used for the second kinase assay, and
the rest of the volume (18 l) was subjected to Western blot analysis as described
above. The second kinase reaction was carried out in a final volume of 50 l: 2
l of the first kinase reaction mixture, 37.5 mM Tris HCl (pH 7.5), 0.75 mM
sodium orthovanadate (pH 10), 0.75 mM EGTA, 0.25 mg of myelin basic pro-
tein/ml, and 0.75% (vol/vol) -mercaptoethanol. The reaction was started by
adding a mixture of ATP and gCl2 to a final concentration of 100 M and 10
m, respectively, and contained 1.66 Ci of [-32P]ATP. The reaction was
incubated for 10 min at 30°C with shaking and stopped by spotting 40 l of this
mixture onto P81 Whatmann disk filters. The filters were dropped into a 75 mM
phosphoric acid solution, washed extensively in the same solution, and dried
after a final acetone wash. The 32P incorporated into myelin basic protein was
quantified by Cerenkov counting. Under these reaction conditions, the incorpo-
ration of 32P into myelin basic protein was linear within the time span of the
assay. We defined 1 U of Cot kinase activity as 1 nmol of phosphate incorporated
into myelin basic protein in 1 min. The specific activity is expressed as milliunits
of Cot activity divided by the amount of Cot protein.
Focus-forming transformation assays. NIH 3T3 cells grown in 100-mm dishes
were transfected with 10 g of wt Cot, trunc-Cot, or the empty vector using the
Lipofectin reagent according to the manufacturers’ instructions (Life Technol-
ogies, Inc.). The day after transfection, the cells were kept in medium supple-
mented with 10% filtered calf serum. After 2 weeks, the cells were washed twice
in PBS, pH 7.4, fixed for 10 min in 75% methanol–25% acetic acid, stained for
1 min with 0.4% crystal violet in 20% ethanol, and washed extensively with water
until the excess stain was removed. All transfections were done in duplicate.
In vitro degradation assays. Transcription-translation assays were performed
with the pcINEO HA-wt Cot and pcINEO HA-trunc-Cot constructs using the
TNT coupled reticulocyte lysate system (Promega) and [35S]methionine and
[35S]cysteine, according to the manufacturer’s instructions. Degradation reac-
tions were performed in a final volume of 20 l containing 20 mM HEPES (pH
7.4), 5 mM EGTA, 5 mM EDTA, 1 l of corresponding labeled kinase, and 0.2
to 0.4 g of purified rat liver 20S proteasome (5). Control reaction mixtures
contained either no proteasome or proteasome plus 20 M MG132 or 10 M
lactacystin. Each reaction was terminated by adding SDS loading buffer, and the
samples were resolved on SDS–10% PAGE gels and vacuum dried. The radio-
labeled proteins were visualized and quantified by Instant Imager analysis (Per-
kin-Elmer). Degradation assays were also performed with 1.5 g of recombinant
GST-Cot390-466 or with 1.5 g of recombinant GST. After the in vitro degrada-
tion reactions, GST-Cot390-466 and GST were visualized in SDS–10% PAGE gels
stained either with Coomassie blue or immunoblotted with anti-Cot antibody or
anti-GST-antibodies as described above.
RESULTS
trunc-Cot exhibits higher levels of steady-state expression
than wt Cot. In order to determine the steady-state expression
of wt Cot and trunc-Cot, we analyzed the amounts of these
proteins in total extracts of HEK293 cells 24 h after transfec-
tion with 10 g of pcINEO HA-wt Cot, pcINEO HA-trunc-
Cot, or pcINEO HA. In Western blots, it was apparent that
these cells expressed higher steady-state levels of trunc-Cot
than wt Cot (Fig. 1A). However, RT-PCR analysis of the same
transfected cells indicated that the mRNA levels of both wt
Cot and trunc-Cot were very similar (Fig. 1B). The higher
levels of protein expression of transfected trunc-Cot were ob-
served with two different anti-Cot antibodies as well as with an
anti-HA antibody, and the quantification of 10 independent
experiments indicated that the expression of trunc-Cot was
2.6-fold  0.4 fold (mean  standard deviation) higher than
the steady-state levels of wt Cot.
The steady-state expression levels of wt Cot and trunc-Cot
proteins were also examined at different times after transfec-
tion (12, 24, 36, and 44 h). Moreover, the Western blot analyses
of the wt Cot and trunc-Cot proteins were performed with total
cell extracts as well as with the 1% NP-40-soluble and -insol-
uble fractions from transfected cells. As expected, in total cell
extracts the expression levels of both wt Cot and trunc-Cot
proteins increased with time. However, at all times after trans-
fection, more trunc-Cot accumulated in the cells than wt Cot
(Fig. 1C). The higher expression levels of trunc-Cot were also
observed after transfection of equal amounts of wt Cot and
trunc-Cot plasmids in other cell lines (Jurkat, Cos-7, and
HeLa) and appeared to be independent of the transfection
method (DEAE-dextran, calcium-phosphate, Lipofectamine,
or electroporation) or the type of vector (pcINEO or pEF-
BOS). Nor was this effect influenced by the type of fusion
protein transfected, as the difference in levels was also ob-
served without tag or GST fused to wt Cot and to trunc-Cot
(data not shown). The higher expression levels of trunc-Cot
compared to wt Cot in the 1% NP-40-soluble fraction could be
detected at different times after transfection (Fig. 1C). Fur-
thermore, 24 h after transfection both wt Cot and trunc-Cot
proteins appeared in the 1% NP-40-insoluble fraction (Fig.
1C), and the wt Cot and trunc-Cot from this fraction were only
partially solubilized after treatment with 6 M guanidinium
chloride (data not shown). Cytoplasmic aggregates of trunc-
Cot and wt Cot could be detected by immunocytochemistry in
HEK293 and Cos-7 cells 48 h after transfection with HA-trunc-
Cot or HA-wt Cot, probably due to this insoluble protein
fraction (data not shown). As a consequence, we performed all
the subsequent experiments 14 to 20 h after cell transfection,
when both wt Cot and trunc-Cot are completely soluble in 1%
NP-40.
trunc-Cot is more slowly degraded than wt Cot. The higher
protein expression levels of trunc-Cot compared to wt Cot
could indicate that the truncated protein has a lower degrada-
tion rate. Thus, we carried out pulse-chase experiments in
HEK293 cells 14 h after their transfection with pcINEO HA-wt
Cot or pcINEO HA-trunc-Cot, and the t1/2 values for both
proteins were determined. The radioactivity incorporated into
wt Cot and trunc-Cot after a 20-min pulse was measured, as
was its decay during the different periods of chase (0 to 240












min). As a result, it became clear that both wt Cot and trunc-
Cot are short-lived proteins (Fig. 2), although the estimated
t1/2 values calculated for wt Cot and trunc-Cot were consis-
tently and significantly different. The t1/2 for wt Cot was 35 min
while that for trunc-Cot was 95 min, indicating that wt Cot is
more rapidly degraded than trunc-Cot.
trunc-Cot and wt Cot are degraded by the proteasome in
situ and in vitro. Having observed a difference in the degra-
dation of both Cot proteins, we studied the pathways involved
in their degradation. After transfection (14.5 h later) of
HEK293 cells with pcINEO HA-wt Cot or pcINEO HA-trunc-
Cot, the cells were treated with different protease inhibitors for
7.5 h. The protease inhibitors examined included cystein and a
papain proteases inhibitor, such as E64; serine protease inhib-
itor, such as pefabloc AEBSF; metalloprotease inhibitors, such
as phosporamidon; an inhibitor of tripeptidyl peptidase, such
as Z-AAF-CMK; proteasome inhibitors, such as MG132 or
lactacystin; and a calpain inhibitor, such as LLMet, as indi-
cated in Materials and Methods. Total cell extracts were sub-
jected to Western blot analysis, and the steady-state levels of
both wt Cot and trunc-Cot proteins in the presence and ab-
sence of the inhibitors were determined. A significant increase
in the amount of both wt Cot and trunc-Cot protein with
respect to untreated control cells was only observed after treat-
ment with the proteasome inhibitor 20 M MG132 (Fig. 3A).
Incubation of wt Cot- and trunc-Cot-transfected cells with 10
M lactacystin (or 20 M MG132 [data not shown]) resulted
in the accumulation of both proteins not only in the 1% NP-
40-soluble fraction but also in the insoluble fraction (Fig. 3B).
The accumulation of both proteins after proteasome inhib-
itor treatment did not result in the appearance of high-molec-
ular-weight species of trunc-Cot or wt Cot, which would sug-
FIG. 1. Expression of wt Cot and trunc-Cot in HEK293 transfected cells. (A and B) Cells were transfected with pcINEO HA-wt Cot (10 g),
pcINEO HA-trunc-Cot (10 g), or pcINEO HA (10 g), and 24 h after transfection wt Cot and trunc-Cot protein and mRNA levels were analyzed.
wt Cot and trunc-Cot protein levels were determined by Western blot analysis using the anti-Cot monoclonal antibody (Calbiochem) (A). The same
PVDF membrane was probed with an anti-PDI antibody as a control of protein loading. The data shown correspond to 30 PCR cycles, and the
amount of product amplified (62 to 373 nucleotides [nt] of HA-wt-Cot, 62 to 373 nt of HA-trunc-Cot, and 1,292 to 1,479 nt of -actin) was
proportional to the abundance of the starting material (B). (C) Quantification of the expression of wt Cot and trunc-Cot in total extracts at different
times after transfection (12, 24, 36, and 44 h), as well as in soluble and insoluble 1% NP-40 fractions of HEK293 cells transfected with pcINEO
HA-wt Cot (10 g) or pcINEO HA-trunc-Cot (10 g). wt Cot and trunc-Cot were detected by Western blot analysis with anti-Cot antibodies either
generated in the laboratory (6) or commercially available (Calbiochem). As a control of protein loading, membranes were also probed with an
anti-PDI antibody. The pixel intensities of the different wt Cot and trunc-Cot bands were quantified with GelDoc 200 (Bio-Rad) and corrected to
the pixel intensity of PDI. The graphs shows the mean  standard deviation of the intensities of the different wt Cot and trunc Cot bands from
three different experiments, assuming a value of 1 for the intensity obtained for wt Cot 24 h after transfection. , wt Cot; , trunc-Cot.












gest the existence of polyubiquitylated forms of Cot. However,
this was further examined by enhancing the possible formation
of trunc-Cot or wt Cot polyubiquitylated forms. Thus, the cells
were cotransfected with wt Cot or trunc-Cot plasmids together
with pCMV-His-ubiquitin, and 14.5 h after transfection the
cells were incubated for another 7.5 h in the presence or
absence of proteasome inhibitors. Under these conditions, we
were still unable to detect higher-molecular-weight forms of wt
Cot or trunc-Cot in total cell extracts, even in the presence of
20 M MG132 (data not shown) or 10 M lactacystin (Fig.
3C). However, when an antiubiquitin antibody was used in-
stead of the anti-Cot antibody, high-molecular-weight polyu-
biquitylated proteins did appear to accumulate in the same
extracts in the presence of 10 M lactacystin (Fig. 3C). In an
attempt to enrich the fraction with wt Cot and trunc-Cot, both
proteins were immunoprecipitated from 1 mg of protein ex-
tracted from the same cells transfected. However, in Western
blotting with the antiubiquitin or anti-Cot antibody even in the
presence of 10 M lactacystin, no polyubiquitylated forms of
wt Cot or trunc-Cot could be detected (Fig. 3C). On the other
hand, neither wt Cot nor trunc-Cot could be detected by West-
ern blot analysis with anti-Cot antibody in the enriched His-
ubiquitin fraction obtained by affinity chromatography on Ni2
columns (data not shown). Nevertheless, it does appear that
the newly synthesized wt Cot and trunc-Cot are also catabo-
lized via the proteasome, since in pulse-chase experiments of
HEK293 cells transfected 12 h earlier with pcINEO HA-wt Cot
or pcINEO HA-trunc-Cot and incubated or not with 10 M
lactacystin, the proteasome inhibitor clearly prevented the deg-
radation of both newly synthesized trunc-Cot and wt Cot (Fig.
3D).
To further address the role of the proteasome in wt Cot and
trunc-Cot stability, degradation experiments were conducted
with in vitro-transcribed and -translated wt Cot and trunc-Cot
together with 20S proteasome purified from rat liver (4, 5). In
this assay, about 55% of wt Cot was degraded 30 min after
incubating with the 20S proteasome, while only 20% of trunc-
Cot was degraded in this time (Fig. 4A). No degradation was
observed in the absence of the proteasome, and degradation
was completely prevented by the addition of 10 M lactacystin
(Fig. 4A). All these data indicate that both wt Cot and trunc-
Cot are targets for proteasome degradation, both in situ as well
as in vitro, and that wt Cot is more sensitive to degradation
than trunc-Cot.
The amino acid 435 to 457 region within the C terminal of wt
Cot targets the protein to proteasome degradation. The
shorter half-life of wt Cot compared to trunc-Cot may be due
to the main structural difference between the two proteins,
which resides in the C terminal (12, 42). Thus, the C-terminal
domain of wt Cot may contain a strong signal that targets the
protein for degradation by the proteasome. To test this hy-
pothesis, we transferred the wt Cot C terminal (amino acids
390 to 467) to the C terminus of EYFP, a fusion construct we
named pEYFP-Cot390-467. Fluorescence-activated cell sorter
analysis was performed 20 h after transfection of HEK293 cells
with pEYFP or with pEYFP-Cot390-467. Both pools of trans-
fected cells had a similar percentage of fluorescent cells (about
50%), but the mean fluorescence was systematically lower in
cells expressing EYFP-Cot390-467 than in EYFP-transfected
cells (data not shown).
To study the degradation of both proteins, HEK293 cells
were transfected with either pEYFP, pEYFP-Cot390-467, or
both plasmids together. After transfection (14.5 h later), cells
were incubated with cycloheximide (100 g/ml) for different
time periods and the protein accumulated in the total cell
extracts was examined using an anti-EYFP antibody in West-
ern blotting. The expression of EYFP-Cot390-467 was lower
than that of EYFP even before the addition of cycloheximide
(Fig. 5A) and, in agreement with the t1/2 of 24 h previously
reported for EYFP (16), the amount of EYFP did not change
significantly over time in the presence of cycloheximide (Fig.
5A). However, in sharp contrast to the stability exhibited by
EYFP, the amount of EYFP-Cot390-467 declined steadily after
the addition of cycloheximide, indicating that the fusion of the
C-terminal domain of wt Cot to EYFP conferred instability to
the protein (Fig. 5A).
Further experiments were performed on HEK293 cells
14.5 h after cotransfection of pEYFP or pEYFP-Cot390-467
together with pCMV-His-ubiquitin; the cells were incubated
for a further 7.5 h in the presence or absence of 10 M
lactacystin. As a consequence of inhibiting the proteasome,
EYFP-Cot390-467 but not EYFP accumulated in these cells
FIG. 2. Degradation of wt Cot and trunc-Cot in HEK293 trans-
fected cells. Immunoprecipitation of 35S-labeled wt Cot and trunc-Cot
from HEK293 cells transfected with 10 g of pcINEO HA-wt Cot or
10 g of pcINEO HA-trunc-Cot after a 20-min pulse-label and a chase
for the times indicated (20, 40, 60, 120, and 240 min). The proteins
immunoprecipitated were resolved by SDS-PAGE and visualized by
autoradiography. The radioactivity incorporated was quantified using
an Instant Imager. The figure shows one experiment, and the graph
shows the mean  standard deviation of the radioactivity incorporated
in four experiments. The radioactivity incorporated into wt Cot or
trunc-Cot after the 20-min pulse was considered 100%. The degrada-
tion of both proteins correlated with one-phase exponential equations
fit to each data set, with R2  0.975 for wt Cot and R2  0.9736 for
trunc-Cot. The graph also shows a representation of the decay as a log
plot. Œ, wt Cot; , trunc-Cot.












FIG. 3. Levels of wt Cot and trunc-Cot expression after treatment of HEK293 transfected cells with different protease inhibitors. (A) Total
extracts of HEK293 cells 14.5 h after transfection with 10 g of pcINEO HA-wt Cot or 10 g of pcINEO HA-trunc-Cot were further incubated
for 7.5 h in the presence of different protease inhibitors (10 M Z-AAF-CMK, a tripeptidyl peptidase inhibitor; 20 M LLMet, a calpain II
inhibitor; 20 M MG132, a proteasome inhibitor; 20 M phosporamidon, a metalloprotease inhibitor; 1 mM prefabloc AEBSF, a serine protease
inhibitor; or 20 M E64, a cysteine protease inhibitor) as indicated in Materials and Methods. Total extracts were analyzed by Western blotting
using anti-Cot (Calbiochem) and anti-PDI antibodies. The figure shows representative results of one of the three experiments performed. (B) Cells
transfected as indicated for panel A and incubated in the presence or absence of 10 M lactacystin were lysed in lysis buffer, and both the 1%
NP-40-soluble and -insoluble fractions were analyzed by Western blotting with an anti-Cot antibody (Calbiochem). (C) Total extracts of cells 14.5 h
after transfection with 5 g of pcDNA3.1 HA-wt Cot or 5 g of pcDNA3.1 HA-trunc-Cot together with 5 g of pCMV-His-ubiquitin, which were
further incubated for 7.5 h in the presence or absence of 10 M lactacystin, were analyzed by Western blotting with anti-Cot antibody (Calbiochem)
or with antiubiquitin antibody. Both wt Cot and trunc-Cot were immunoprecipitated from the same transfected cells and analyzed by Western
blotting with antiubiquitin antibody and anti-Cot antibody. The figure shows representative results of one of the three experiments performed.
(D) Accumulation of newly synthesized wt Cot and trunc-Cot after lactacystin (10 M) incubation. 35S-labeled wt Cot and trunc-Cot were
immunoprecipitated from HEK293 cells transfected with 10 g of pcINEO HA-wt Cot or 10 g of pcINEO HA-trunc-Cot after a 20-min pulse
and 3-h chase (wt Cot) or 4-h chase (trunc-Cot) in the presence or absence of 10 M lactacystin. The proteins were resolved by SDS-PAGE and
visualized by autoradiography. The figure shows representative results of one of the three experiments performed.












(Fig. 5B). Thus, we examined whether the C terminal of wt Cot
could also target a protein for degradation by the 20S protea-
some in vitro. To this end, we fused the C terminal of wt Cot
to the C terminus of GST, and the recombinant GST-Cot390-467
protein was analyzed in the in vitro degradation assay. The
GST-Cot390-467 fusion protein was susceptible to degradation
by the 20S proteasome and, as expected, 20 M MG132 or 10
M lactacystin prevented this degradation (Fig. 5C). In control
experiments carried out with recombinant GST, the 20S pro-
teasome was unable to degrade GST (Fig. 5C).
It has recently been reported that protein kinase B (PKB)
regulates Cot-induced NF-B activation by phosphorylating
two residues in the C terminal of wt Cot (31). We therefore
investigated whether PKB activity could modulate the sensitiv-
ity of EYFP-Cot390-467 to proteasome degradation in intact
cells by cotransfecting HEK293 cells with pEYFP-Cot390-467
and a plasmid that expresses a constitutively active form of
PKB, HA-PKB-DD (19). When the protein expression levels
of EYFP-Cot390-467 were determined after treatment of the
transfected cells with cycloheximide (100 g/ml), in the pres-
ence or absence of lactacystin (10 M), it was evident that the
constitutively active form of PKB did not affect the steady-state
expression of EYFP-Cot390-467 in intact cells or its susceptibil-
ity to proteasome degradation (Fig. 6A). To discard the pos-
sibility that the endogenous PI3K-PKB signaling pathway was
already activated in the transfected cells, 2 h after transfection
with EYFP-Cot390-467 the cells were incubated with an inhibi-
tor of PI3K, LY 294002 (50 M), and then for 8 h before the
lysis with cycloheximide (100 M) and LY 294002 (50 M) in
the presence or absence of lactacystin (10 M). The presence
of the PI3K inhibitor did not alter the steady-state expression
levels of EYFP-Cot390-467 or its susceptibility to degradation
via the proteasome (Fig. 6B). Similar results were obtained
when EYFP-Cot390-467 was cotransfected with a construct that
expresses a constitutive dominant-negative form of PKB
(PKB-CaaX; data not shown).
To further define the region within the wt Cot C-terminal
domain implicated in targeting the EYFP fusion protein for
proteasome degradation, different pEYFP-Cot390-n constructs
were analyzed, namely, pEYFP-Cot390-467, pEYFP-Cot390-457,
pEYFP-Cot390-446, pEYFP-Cot390-435, and pEYFP-Cot390-424.
When transfected into HEK293 cells and incubated 14.5 h
after transfection for 8 h with 100 g of cycloheximide/ml in
the presence or absence of 10 M lactacystin, EYFP-Cot390-457
presented similar levels of expression as EYFP-Cot390-467.
Both proteins were hardly detectable in Western blotting after
exposure for 8 h to cycloheximide (100 g/ml); nevertheless,
the presence of lactacystin (10 M) inhibited their degradation
(Fig. 6C). However, when a further 11 amino acids were de-
leted from the C terminal of EYFP-Cot390-457, the resulting
protein, EYFP-Cot390-446, exhibited significantly higher steady-
state levels of protein expression than those observed for
EYFP-Cot390-457 or EYFP-Cot390-467. Moreover, treatment
with cycloheximide (8 h) did not diminish its level of expression
(Fig. 6C). Furthermore, EYFP-Cot390-435 and EYFP-Cot390-424
were expressed at steady-state protein levels similar to those of
EYFP-Cot390-446 (Fig. 6C) and EYFP (data not shown).
Having defined what appears to be the C-terminal limit of
the sequence in wt Cot that targets it for proteasome degra-
dation, we set out to define the more-N terminal by using a
similar strategy. The generated constructs pEYFP-Cot414-457,
pEYFP-Cot426-457, pEYFP-Cot435-457, and pEYFP-Cot445-457
were transfected into HEK293 cells, and the transfected cells
were treated as described above. The EYFP-Cot445-457 fusion
protein was not susceptible to degradation via proteasome,
indicating that although this 12-amino-acid region of the wt
Cot C-terminal domain (amino acids 445 to 457) does contain
part of the signal necessary for degradation (Fig. 6C), it is not
sufficient to target the fusion protein to proteasome degrada-
tion (Fig. 6D). However, the fusion of the amino acid 435 to
457 region within the wt Cot C-terminal domain to EYFP did
efficiently target the protein for degradation via proteasome
(Fig. 6D).
trunc-Cot exhibits higher specific kinase activity than wt
Cot. We also wanted to know whether the increased levels of
protein expression of trunc-Cot were correlated with an in-
creased activation of the different signal transduction pathways
regulated by Cot. Cot up-regulates the classical MAP kinase
pathway (20, 53). Therefore, we analyzed the phosphorylation
state of endogenous Erk-1 and Erk-2 in total extracts of
HEK293 cells 20 h after transfection with pcINEO HA-wt Cot
and pcINEO HA-trunc-Cot. Both wt Cot and trunc-Cot acti-
FIG. 4. Degradation of wt Cot and trunc-Cot by the 20S protea-
some. Transcribed and translated wt Cot and trunc-Cot were incu-
bated for the indicated times with 20S proteasome in the presence or
absence of 10 M lactacystin. The proteins were then resolved by
SDS-PAGE and visualized by autoradiography, and the incorporated
radioactivity was quantified by using an Instant Imager. The figure
shows one representative experiment, and the graph shows the mean
standard deviation of two experiments performed in duplicate.












vated endogenous Erk-1 and Erk-2, although a higher degree
of activation was observed upon transfection of trunc-Cot (Fig.
7A).
It has previously been shown that Cot activity up-regulates
the transcription factor AP-1 (7, 13). A reporter construct has
been generated that contains the 73-bp collagenase pro-
moter linked to the luciferase reporter gene (73 pcol-Luc);
this promoter region contains only the AP-1 response element
and has been extensively used to study AP-1 activation (refer-
ences 7 and 13 and references therein). Different amounts of
pEF-BOS wt Cot, pEF-BOS trunc-Cot, and pEF-BOS were
cotransfected together with the 73 pcol-Luc, and Luc activity
was measured 20 h after transfection. Cells transfected with
trunc-Cot up-regulated AP-1 transcription factor activity to a
greater extent than cells expressing wt Cot (Fig. 7B). Interest-
ingly, about 10-fold more wt Cot plasmid than trunc-Cot plas-
mid was required to reach similar activation levels of the AP-1
responsive element (Fig. 7B).
It has been proposed that the ability of Cot to induce cellular
transformation (12, 13) depends on its ability to activate the
AP-1 transcription factor (13). We therefore assessed whether
the augmented activation of the AP-1 responsive element by
trunc-Cot was correlated with a greater degree of cellular
transformation. The transfection of pcINEO HA-wt Cot into
NIH 3T3 cells induced the appearance of transformed foci
after 2 weeks in culture as previously reported (Fig. 7C) (12,
13). However, the number of transformed foci was clearly
higher in NIH 3T3 cells transfected with pcINEO HA-trunc-
Cot (Fig. 7C). We then decided to measure the activity of Cot
as MAP kinase kinase kinase 1 (MKKK1) in extracts prepared
from cells transfected with wt Cot and trunc-Cot. From equal
quantities (10 g) of the 1% NP-40-soluble fractions of cells
transfected with pcINEO HA-Cot wt, pcINEO HA-trunc-Cot
(20 h after transfection), wt Cot, and trunc-Cot were immuno-
precipitated and Cot activity was determined. The Cot activity
(in milliunits per milligram of total protein extract) from trunc-
Cot-transfected cells was 10-fold higher (1) than that derived
from wt Cot-transfected cells (Fig. 7D), These results are qual-
itatively not unexpected since, as mentioned above, trunc-Cot
has higher protein expression levels than wt Cot. However,
quantification of the amount of Cot protein that was immuno-
precipitated showed an approximately 2.6-fold difference in
the protein content in immunoprecipitates from trunc-Cot-
and wt Cot-transfected extracts. This quantification allowed us
FIG. 5. The C terminal of wt Cot triggers its degradation by the proteasome. (A) HEK293 cells 14.5 h after transfection with 10 g of
pEYFP-Cot390-467 or 10 g of pEYFP or cotransfected with 5 g of pEYFP-Cot390-467 together with 5 g of pEYFP were further incubated with
100 g of cycloheximide/ml for different times (0, 30, 60, 120, 240, and 480 min). The total extracts were Western blotted and probed with the
anti-EYFP antibody. The figure shows one of two experiments performed in duplicate. (B) Total extracts of cells 14.5 h after transfection with 5
g of pEYFP or 5 g of pEYFP-Cot390-467 together with 5 g of pCMV-His-ubiquitin and further incubated for 7.5 h in the presence or absence
of 10 M lactacystin. The extracts were Western blotted and probed with anti-EYFP. Similar results were obtained in two different experiments
performed in duplicate. (C) Recombinant GST-Cot390-467 was subjected to in vitro degradation by the 20S proteasome for 20 and 40 min.
GST-Cot390-467 was also incubated with 20S proteasome in the presence of 20 M MG132 or 10 M lactacystin. The different samples were
resolved by SDS-PAGE and Western blotted to be probed with an anti-C-terminal Cot antibody. Similar results were obtained in three experiments
performed in duplicate. Recombinant GST was subjected to in vitro degradation for 20, 40, 60, and 80 min by the 20S proteasome. The different
samples were resolved by SDS-PAGE followed by Western blotting, which was probed with anti-GST antibody. Similar results were obtained in
two experiments performed in duplicate.












to estimate the specific activity (in milliunits per amount of Cot
protein) of both trunc-Cot and wt Cot. As a result, it appeared
that trunc-Cot exhibited 3.8-fold (0.4) higher kinase specific
activity than wt Cot (Fig. 7D). A similar difference in the
specific activity was also observed between trunc-Cot and wt
Cot in autophosphorylation assays (data not shown).
Identification of the region within the C-terminal domain of
Cot responsible for the inhibition of wt Cot activity. Finally, we
set out to determine the region within the C-terminal domain
of wt Cot that inhibits Cot specific activity, as well as to discard
the possibility that the 18 amino acids inserted in trunc-Cot
were responsible for its higher activity. For this purpose, we
generated different wt Cot constructs with increasing portions
of the C-terminal domain deleted, namely: pcINEO HA-
Cot424, pcINEO HA-Cot435, pcINEO HA-Cot446, and pcINEO
HA-Cot457. Each of these constructs, as well as pcINEO
HA-wt Cot(467) and pcINEO HA-trunc-Cot, were cotrans-
fected together with 73 pcol-Luc in HEK293 cells, and Luc
activity was measured 20 h after transfection. While Cot424
activated the AP-1 response element to the same extent as
trunc-Cot (Fig. 8A), the activation produced by the Cot435,
Cot446, and Cot457 proteins decreased in a stepwise fashion,
with Cot457 activating the reporter to the same extent as wt
Cot(467). We next decided to determine the specific activity of
the different Cot deletion mutants. The different Cot con-
structs were transfected in HEK293 cells, and Western immu-
noblot analysis of the steady-state expression levels as well as
the Cot activity of the different Cot proteins were determined.
In agreement with the data obtained above (Fig. 6C), trunc-
Cot, Cot424, Cot435, and Cot446 exhibited expression levels ap-
proximately 2.6-fold higher than those of Cot457 and wt
Cot(467) (Fig. 8B). The specific activity of the Cot457 protein
was similar to that of wt Cot(467), and further deletions within
the wt Cot C-terminal region produced a gradual increase in
the specific activity of Cot mutants, with Cot424 demonstrating
a similar specific activity as trunc-Cot (Fig. 8B). It is notewor-
thy that Cot446, with a transformation activity between that of
wt Cot and trunc-Cot (data not shown), exhibited only 1.5-fold-
higher Cot activity per mg of total protein extract than wt Cot;
however its 2.6-fold-higher steady-state protein expression
compared to wt Cot provided it about 4.6-fold-higher specific
activity compared to wt Cot(467).
DISCUSSION
Cot/tpl-2 has been implicated in cellular activation and cel-
lular transformation. Thus, Cot/tpl-2 (25, 53), together with
c-Raf (18, 30, 37) and c-Mos (43, 51, 57), are three proto-
FIG. 6. The amino acid 435 to 457 region within the C terminal of wt Cot confers susceptibility to proteasome degradation and is independent
of PKB activity. (A) HEK293 cells were cotransfected with 5 g of EYFP-Cot390-467 together with 15 g of HA-PKB-DD or empty vector, and
14.5 h after transfection the cells were further incubated with 100 g of cycloheximide/ml in the presence or absence of 10 M lactacystin as
described in Materials and Methods. The figure is representative of the three experiments performed. (B) Two hours after the transfection of
HEK293 cells with 10 g of EYFP-Cot390-467, the cells were incubated with 50 M LY 294002 and the medium was then supplemented with 100
g of cycloheximide/ml and 50 M LY 294002, with and without 10 M lactacystin, for a further 8 h. The figure shows representative results of
the three experiments performed. (C) HEK293 cells were transfected with 10 g of pEYFP-Cot390-467, pEYFP-Cot390-457, pEYFP-Cot390-446,
pEYFP-Cot390-435, or pEYFP-Cot390-424, and after 14.5 h cells were treated as described in the legend for Fig. 5B. Total extracts were Western
blotted and probed with anti-EYFP and anti-PDI antibodies; the figure shows representative results of one of the three experiments. (D) HEK293
cells transfected for 14.5 h with pEYFP-Cot414-457, pEYFP-Cot426-457, pEYFP-Cot435-457, and pEYFP-Cot445-450 were treated as explained above
for panel C. The figure shows one of the two experiments performed in duplicate.












oncogenes that code for MAP kinase kinase kinases that up-
regulate the Erk-1/Erk-2 signal transduction pathway. How-
ever, different modifications convert these proto-oncogenes
into oncogenes. The protein products of both the v-mil onco-
gene and the transforming variants of Raf differ from their
proto-oncogenes in their N-terminal regions (10, 26, 48, 49). In
contrast, the c-mos proto-oncogene and the v-mos oncogene
differ as a consequence of a proviral insertion in the 5 non-
coding region that does not affect the sequence of the protein
product (although some viral strains do also have point muta-
tions within their coding sequence) (9, 69). The rearrangement
of the 3 region of the human Cot gene, as well as of its murine
homologue tpl-2, unmasks their transformation activities, both
oncogenes encoding C-terminal-truncated and -modified pro-
teins (2, 11, 12, 42, 46). In this paper we demonstrate that the
truncation of the C-terminal domain of wt Cot produces an
increase in the total kinase activity of Cot through two different
mechanisms: by an increase in the t1/2 of the protein and by
augmenting the specific activity of the kinase. These two inde-
pendent mechanisms potentiate one another to produce a 10-
FIG. 7. trunc-Cot exhibits a higher transformation capacity and kinase activity than wt Cot. (A) Western blots of P-Erk in total extracts of
HEK293 cells 20 h after transfecting with pcINEO HA-wt Cot (10 g), pcINEO HA-trunc-Cot (10 g), or pcINEO HA (10 g). As a control of
protein loaded, total Erk-2 levels were tested. The expression of wt Cot and trunc-Cot was also determined with the anti-Cot antibody
(Calbiochem). Similar results were obtained in three different experiments. (B) Different amounts of pEF-BOS wt Cot, pEF-BOS trunc-Cot, or
pEF-BOS (0.01, 0.03, 0.1, or 0.3 g) together with 0.15 g of 73 pcol-Luc were cotransfected in HEK293 cells, and Luc activity was measured
20 h after transfection. The graph shows the means standard deviations of three different experiments performed in duplicate. (C) NIH 3T3 cells
were transfected with 10 g of pcINEO HA-wt Cot, pcINEO HA-trunc-Cot, or pcINEO HA. Cells were cultured for 2 weeks with 10% filtered
calf serum, fixed, and then stained as described in Materials and Methods. The figure shows a representative experiment of the three performed.
(D) Cot activity per milligram of protein extract and Cot specific activity of wt Cot and trunc-Cot immunoprecipitated from HEK293 cells
transfected as described for panel A. Cot activity indicates the milliunits of Cot kinase activity corresponding to 1 mg of transfected extract, with
1 U being 1 nmol of phosphate incorporated into myelin basic protein in 1 min. The specific activity indicates the milliunits of Cot kinase activity
divided by the pixel intensity obtained from the scanned Western blots of the immunoprecipitated wt Cot or trunc-Cot, with a value of 1 being
attributed to the specific activity of wt Cot divided by the pixel intensity of immunoprecipitated wt Cot. The graphs show the means  standard
deviations of three different experiments performed in triplicate.












fold increase in the kinase activity of Cot. As a consequence,
we observed a higher activation state of different MAP kinase
transduction pathways in trunc-Cot-transfected cells, such as
the Erk-1/Erk-2 and the Jnk–AP-1 pathways. Abnormal acti-
vation of these MAP kinase pathways has previously been
associated with cellular transformation (41, 55), and indeed we
have also shown that a higher number of transformed foci were
generated in NIH 3T3 cells transfected with trunc-Cot than
with wt Cot. In agreement with these data, it has been pro-
posed that the ability of wt Cot to induce cellular transforma-
tion (12, 13) depends on its capacity to activate the AP-1
transcription factor (13).
The structural difference between wt Cot and trunc-Cot re-
sides in the 69 amino acids of the C-terminal domain that in
trunc-Cot are replaced by 18 amino acids of unrelated se-
quence. Here we show that the deletion of the last 43 C-
terminal amino acids of wt Cot renders a protein with a similar
activity to that of trunc-Cot. Thus, the domain that represses its
kinase activity resides in amino acids 425 to 467 of wt Cot (Fig.
9), excluding the possibility that the 18-amino-acid insertion at
the C terminal of trunc-Cot enhances its kinase specific activ-
ity. In this context, we also must bear in mind that the C
terminals of wt tpl-2 and wt Cot are homologous, whereas the
10-amino-acid insert in trunc-tpl-2, which also behaves as an
oncogene, does not share any homology with the 18 amino
acids inserted into trunc-Cot (11, 46). Moreover, although the
difference in the kinase specific activity between tpl-2 and
trunc-tpl-2 is unknown, it has been shown that the C terminal
of tpl-2 is capable of inhibiting the kinase activity of trunc-tpl-2
in vitro (11). These data, together with the fact that the Cot
mutants with increasing C-terminal deletions exhibited in-
creased specific activities, indicate that the C-terminal domain
of wt Cot is an autoinhibitory domain. Therefore, by specifi-
cally up-regulating certain extracellular signals, it should be
possible to abolish this C-terminal repression of kinase activity,
perhaps by inducing posttranslational modifications in the Cot
protein. In this context, it should be taken into account that the
phosphorylation of the C-terminal domain of wt Cot by PKB
(31) appeared to have no effect on the MKKK1 activity of wt
Cot (M. Caivano, C. Rodriguez, P. Cohen, and S. Alemany,
personal communication) or on AP-1 activation by wt Cot (31).
The C terminal of wt Cot also plays an important role in
targeting the protein for degradation, as the amino acids 435 to
457 within the wt Cot C-terminal domain appear to be a region
that controls the stability of wt Cot (Fig. 9). In this context, it
is noteworthy that the region between amino acids 435 and
446, as well as the region between amino acids 445 and 457, are
essential regions, but not sufficient, to target the EYFP C-
terminal wt Cot fusion protein for degradation via the protea-
some (Fig. 6C and D). This explains the similar levels of ex-
pression exhibited by Cot446 and trunc-Cot (Fig. 8A). The
recognition-degradation signal contained in the region of
amino acids 435 to 457 from wt Cot is capable of conferring
instability to other unrelated proteins, an essential quality of
the recognition-degradation sequences denominated degron,
and we propose that this proteasome recognition sequence
accounts for the lower t1/2 and the lower steady-state expres-
sion levels of wt Cot compared to trunc-Cot. To our knowl-
edge, this region within wt Cot does not share similarities with
other previously described degrons. Moreover, our data sug-
FIG. 8. Identification of the region within the C-terminal domain
of wt Cot that inhibits Cot specific activity. (A) HEK293 cells were
cotransfected with 0.15 g of pcINEO HA-wt Cot(467), pcINEO HA-
Cot457, pcINEO HA-Cot446, pcINEO HA-Cot435, pcINEO HA-Cot424,
or pcINEO HA-trunc-Cot together with 0.15 g of 73 pcol-Luc, and
Luc activity was measured 20 h after transfection. The graph shows the
means  standard deviations of two different experiments performed
in duplicate. (B) HEK293 cells were transfected with 10 g of pcINEO
HA-wt Cot(467), pcINEO HA-Cot457, pcINEO HA-Cot446, pcINEO
HA-Cot435, or pcINEO HA-Cot424. Western blotting of the total ex-
tracts of HEK293 cells 20 h after transfection with the different
pcINEO Cot constructs was performed as described in the legend for
Fig. 1A. The figure shows one representative result of the three ex-
periments performed. As a control of protein loaded, total PDI levels
were also assessed. Cot activity and Cot specific activity of the different
Cot constructs [wt Cot(467), Cot 457, Cot446, Cot435, and Cot424] were
determined as described in the legend for Fig. 7D. The graphs also
show the means of three experiments  standard deviations.












gest a direct recognition of the Cot degron by the 20S protea-
some. In this context, and considering that the C terminals of
both wt Cot and wt tpl-2 are almost identical, it seems likely
that the C terminal of tpl-2 also confers instability to the
protein. Analysis of putative PEST domains (52) within the C
terminal of wt Cot revealed that the region between amino
acids 415 and 438 is a putative PEST sequence (Fig. 9). How-
ever, the degradation experiments performed with the differ-
ent EYFP-Cot constructs revealed that this sequence does not
play any role in the proteasome recognition-degradation of the
C terminal of wt Cot.
It is accepted that short-lived proteins are mainly degraded
via the proteasome (34, 67), a hypothesis supported by the
results presented here for wt Cot and trunc-Cot. However, our
data also suggest that both wt Cot and trunc-Cot are catabo-
lized via the proteasome in an ubiquitylation-independent
manner. In this context, it should be stressed that although the
vast majority of proteins need to be polyubiquitylated prior to
proteasome degradation, other proteins that do not need to be
polyubiquitylated for proteasome degradation are starting to
be identified (3, 15, 36, 39, 50, 60, 66). However, the possibility
that an isopeptidase activity could hydrolyze the polyubiquitin
chain cannot be excluded.
Interestingly, not only wt Cot but also trunc-Cot is degraded
via the proteasome, indicating that wt Cot could contain more
than one recognition site for proteasome degradation and that
at least one of these is maintained in the trunc-Cot protein
sequence. In this context, the region regulating stability has
been identified in the N-terminal stability-regulating region of
the MAP kinase kinase kinase c-Mos (45, 56). However, con-
sidering that the wt Cot sequence and the wt tpl-2 sequence do
not contain the amino acids described as essential for the
destabilization of c-mos at the specific positions (45, 56), it is
unlikely that wt Cot or wt tpl-2 contain this stability-regulating
region.
The insertion of MLV or MMTV provirus into the tpl-2
gene and the truncation of the Cot gene produce the deletion
of the 3 untranslated region of the tpl-2 or Cot gene that
harbors three copies of the RNA-destabilizing sequence
AUUUA. This results in higher expression levels of the cor-
responding mRNAs (23, 46). Thus, it has been proposed that
this increase in the mRNA levels of the truncated Cot or tpl-2
gene may lead to higher levels of protein expression and there-
fore to cell transformation (23, 46, 63). However, we have
shown here that trunc-Cot exhibits greater cellular transfor-
mation capacity and kinase activity than wt Cot and that trans-
fection of both plasmids renders similar levels of mRNA ex-
pression. Thus, we conclude that, as a consequence of the Cot
gene truncation, regulation is altered at three different levels:
stabilization of the mRNA (23, 46), an increase in the Cot
specific activity, and stabilization of the protein. Moreover, as
shown here, the increase in the kinase specific activity and the
stabilization of the truncated protein induce a 10-fold increase
in Cot kinase activity and, consequently, a higher transforma-
tion capacity.
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